In leading the $10 billion investment in LabGenius, two U.S. venture capital funds Lux Capital and Obvious Ventures reveal a biotech investing strategy not seen from the old guard of life science financing.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,